## Supplementary Information

Analyst

## High-sensitivity visualisation of contaminants in heparin samples by spectral filtering of <sup>1</sup>H NMR spectra

Timothy R. Rudd<sup>a,b</sup>, Davide Gaudesi<sup>a</sup>, Marcelo A. Lima<sup>c</sup>, Mark A. Skidmore<sup>d</sup>, Barbara Mulloy<sup>e</sup>, Giangiacomo Torri<sup>a</sup>, Helena B. Nader<sup>c</sup>, Marco Guerrini<sup>a</sup> and Edwin A. Yates<sup>a,\*</sup>

<sup>a</sup>Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni", Via Giuseppe Colombo, 81 Milano 20133 ITALY <sup>b</sup>School of Biological Sciences, University of Liverpool, P.O. Box 147, Liverpool, L69 3BX United Kingdom <sup>c</sup>UNIFESP - Universidade Federal de São Paulo, Departamento de Bioquímica, Disciplina de Biologia Molecular, Rua Três de Maio 100, 4 andar - Vila Clementino, 04044-020 BRAZIL

<sup>d</sup>Institute for Science and Technology in Medicine, Keele University Keele, Staffordshire ST5 5BG United Kingdom

<sup>e</sup>National Institute for Biological Standards and Control, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom

List of material within:

Figure S1 Illustrative plot of the binned and cut heparin-OSCS [0.25-25%] spectra.

Figure S2. Reconstructed spectra of the OSCS [0.25 - 25 %] contaminant.

Figure S3 Illustrative plot of the binned and cut heparin-OSDxS/OSAS [2-20%] spectra.

Figure S4. Reconstructed spectra of the OSAS [2 - 20 %] contaminant.

Figure S5. Reconstructed spectra of the OSDxS [2 - 20 %] contamination.

**Figure S6** 2D-COS analysis of unpurified GAG extract (1, 5 5and 10 % (w/w)) added to a pharmaceutical heparin sample.

**Figure S7** 2D-COS analysis of unpurified sulfated GAG extract (1, 5 and 10 % (w/w)) added to a pharmaceutical heparin samples.

**Figure S8** The N-acetyl region of the 2D-COS. Difference analysis of (**A**) unpurified GAG extract (5% w/w) and (**B**) sulfated GAG extract (5% w/w) added to a pharmaceutical heparin sample.



Figure S1 Illustrative plot of the binned and cut heparin-OSCS [0.25-25%] spectra.



**Figure S2.** Reconstructed spectra of the OSCS [0.25 - 25 %] contaminant. The above spectra were created by subtracting the heparin 2D-COS power spectrum away from the specific OSCS [0.25 - 25 %] plus heparin dataset power spectrum. The power spectrum is the diagonal of the 2D-COS spectrum, or the variance of the covariance matrix.



Figure S3 Illustrative plot of the binned and cut heparin-OSDxS/OSAS [2-20%] spectra.



**Figure S4**. Reconstructed spectra of the OSAS [2 - 20 %] contaminant. The above spectra were created by subtracting the heparin 2D-COS power spectrum away from the specific OSAS [2 - 20 %] plus heparin dataset power spectrum. The power spectrum is the diagonal of the 2D-COS spectrum, or the variance of the covariance matrix.



**Figure S5**. Reconstructed spectra of the OSDxS [2 - 20 %] contamination. The above spectra were created by subtracting the heparin 2D-COS power spectrum away from the specific OSDxS [2 - 20 %] plus heparin dataset power spectrum. The power spectrum is the diagonal of the 2D-COS spectrum, or the variance of the covariance matrix.



**Figure S6** 2D-COS analysis of unpurified GAG extract <sup>1</sup> (1, 5 5and 10 % (w/w)) added to a pharmaceutical heparin sample. Panels A (1% w/w), C (5% w/w) and E (10 w/w) show the 2D-COS spectra generated when the contaminants were added to the heparin library. Panels B, D and F are the difference 2D-COS spectra, the contaminated heparin added to the heparin library 2D-COS minus the 2D-COS spectra of the heparin

dataset.



**Figure S7** 2D-COS analysis of unpurified sulfated GAG extract <sup>1</sup> (1, 5 and 10 % (w/w)) added to a pharmaceutical heparin samples. Panels A (1% w/w), C (5% w/w) and E (10 w/w) show the 2D-COS spectra generated when the contaminants were added to the heparin library. Panels B, D and F are the difference

2D-COS spectra, the contaminated heparin added to the heparin library 2D-COS minus the 2D-COS spectra of the heparin dataset.



**Figure S8** The N-acetyl region of the 2D-COS. Difference analysis of (**A**) unpurified GAG extract <sup>1</sup> (5% w/w) and (**B**) sulfated GAG extract <sup>1</sup> (5% w/w) added to a pharmaceutical heparin sample. The difference spectra were generated by subtracting the 2D-COS spectrum of the heparin reference library from the 2D-COS spectrum of the heparin reference library including the contaminated heparin sample. The multiple cross peak correlations reveal how complicated the pollutant is in this case.

<sup>1.</sup> M. Guerrini, Z. Zhang, Z. Shriver, A. Naggi, S. Masuko, R. Langer, B. Casu, R. J. Linhardt, G. Torri and R. Sasisekharan, *Proc Natl Acad Sci U S A*, 2009, **106**, 16956-16961.